SGK1

Summary

SGK1 (serum/glucocorticoid regulated kinase 1, HGNC:10810) is a protein-coding gene on chromosome 6q23.2, encoding Serine/threonine-protein kinase Sgk1 (O00141). Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. In precision oncology, SGK1 Overexpression is associated with resistance to Alpelisib in Breast Cancer (CIViC Level B); 1 further curated variant–drug associations are listed below.

This gene encodes a serine/threonine protein kinase that plays an important role in cellular stress response. This kinase activates certain potassium, sodium, and chloride channels, suggesting an involvement in the regulation of processes such as cell survival, neuronal excitability, and renal sodium excretion. High levels of expression of this gene may contribute to conditions such as hypertension and diabetic nephropathy. Several alternatively spliced transcript variants encoding different isoforms have been noted for this gene.

Source: NCBI Gene 6446 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 81 total — 1 likely-pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Precision-oncology evidence (CIViC): 2 curated variant–drug associations
• Cancer driver (intOGen): activating (oncogene-like) across 4 cancer types
• MANE Select transcript: NM_001143676

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10810
Approved symbol	SGK1
Name	serum/glucocorticoid regulated kinase 1
Location	6q23.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000118515
Ensembl biotype	protein_coding
OMIM	602958
Entrez	6446

Gene structure

Transcript identifiers

Ensembl transcripts: 31 — 15 retained_intron, 11 protein_coding, 5 protein_coding_CDS_not_defined

ENST00000237305, ENST00000367855, ENST00000367857, ENST00000367858, ENST00000413996, ENST00000460769, ENST00000461976, ENST00000472859, ENST00000473704, ENST00000474427, ENST00000475719, ENST00000475882, ENST00000477460, ENST00000484353, ENST00000485771, ENST00000489458, ENST00000490149, ENST00000524387, ENST00000524764, ENST00000524929, ENST00000525700, ENST00000525877, ENST00000528577, ENST00000530421, ENST00000531575, ENST00000531782, ENST00000532021, ENST00000532856, ENST00000533224, ENST00000534658, ENST00000944482

RefSeq mRNA: 5 — MANE Select: NM_001143676 NM_001143676, NM_001143677, NM_001143678, NM_001291995, NM_005627

CCDS: CCDS47476, CCDS47477, CCDS47478, CCDS5170, CCDS78184

Canonical transcript exons

ENST00000367858 — 14 exons

Exon	Start	End
ENSE00001445793	134317392	134318112
ENSE00003459946	134171637	134171732
ENSE00003470842	134171023	134171178
ENSE00003538253	134170826	134170915
ENSE00003538880	134174511	134174586
ENSE00003539710	134207356	134207431
ENSE00003554684	134169256	134170435
ENSE00003572454	134173274	134173357
ENSE00003580144	134173023	134173154
ENSE00003595366	134172662	134172774
ENSE00003631036	134172193	134172316
ENSE00003632299	134173462	134173566
ENSE00003656301	134174005	134174080
ENSE00003685714	134261933	134262148

Expression profiles

Bgee: expression breadth ubiquitous, 299 present calls, max score 99.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 143.7802 / max 3666.2799, expressed in 1809 samples.

FANTOM5 promoters (31 alternative TSS)

Promoter ID	TPM avg	Samples expressed
75647	123.7557	1802
75651	6.8093	653
75650	5.3452	1341
75649	1.1726	551
75681	1.1179	189
75678	0.6272	130
75682	0.5203	114
75680	0.5100	120
75652	0.4945	156
75659	0.4196	96

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
palpebral conjunctiva	UBERON:0001812	99.60	gold quality
eye	UBERON:0000970	99.44	gold quality
right lung	UBERON:0002167	99.39	gold quality
choroid plexus epithelium	UBERON:0003911	99.39	gold quality
cervix squamous epithelium	UBERON:0006922	99.27	gold quality
gingival epithelium	UBERON:0001949	99.20	gold quality
parietal pleura	UBERON:0002400	99.20	gold quality
cervix epithelium	UBERON:0004801	99.19	gold quality
mucosa of urinary bladder	UBERON:0001259	99.17	gold quality
gingiva	UBERON:0001828	99.14	gold quality
nasal cavity epithelium	UBERON:0005384	99.14	gold quality
lower lobe of lung	UBERON:0008949	99.08	gold quality
gall bladder	UBERON:0002110	98.94	gold quality
pleura	UBERON:0000977	98.88	gold quality
pigmented layer of retina	UBERON:0001782	98.88	gold quality
retina	UBERON:0000966	98.86	gold quality
olfactory bulb	UBERON:0002264	98.83	gold quality
metanephric glomerulus	UBERON:0004736	98.82	gold quality
renal glomerulus	UBERON:0000074	98.78	gold quality
upper leg skin	UBERON:0004262	98.70	gold quality
mucosa of transverse colon	UBERON:0004991	98.68	gold quality
nephron tubule	UBERON:0001231	98.63	gold quality
left ovary	UBERON:0002119	98.59	gold quality
medial globus pallidus	UBERON:0002477	98.57	gold quality
pericardium	UBERON:0002407	98.56	gold quality
kidney epithelium	UBERON:0004819	98.52	gold quality
squamous epithelium	UBERON:0006914	98.51	gold quality
parotid gland	UBERON:0001831	98.44	gold quality
nasal cavity mucosa	UBERON:0001826	98.40	gold quality
globus pallidus	UBERON:0001875	98.38	gold quality

Single-cell (SCXA)

Detected in 16 experiment(s), a significant marker in 15.

Experiment	Marker?	Max mean expression
E-MTAB-10137	yes	1980.85
E-HCAD-35	yes	85.06
E-MTAB-6701	yes	75.80
E-GEOD-125970	yes	67.10
E-MTAB-10553	yes	45.80
E-MTAB-6678	yes	42.46
E-MTAB-10287	yes	37.62
E-GEOD-84465	yes	37.49
E-CURD-46	yes	33.96
E-MTAB-9467	yes	27.98
E-HCAD-9	yes	18.40
E-HCAD-1	yes	17.43
E-GEOD-135922	yes	7.24
E-GEOD-130148	yes	6.28
E-MTAB-8530	no	765.94

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): APC, AR, CTNNB1, EGR1, GATA2, GLI1, IRF6, MECP2, MYC, NFAT5, NFKB, NR3C1, NR3C2, OVOL1, PGR, POLR2A, PPARG, RELA, SP1, SP3, TCF7L2, TP53, TSC22D3

miRNA regulators (miRDB)

150 targeting SGK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-12136	99.98	72.81	5713

Literature-anchored findings (GeneRIF, showing 40)

• Excessive transcription of the human serum and glucocorticoid dependent kinase hSGK1 in lung fibrosis (PMID:12077559)
• single nucleotide polymorphisms of SGK linked to variations in blood pressure (PMID:12215463)
• Glucocorticoidss stimulate sgk1 expression in human epithelial cells via activation of a GRE in the 5’-flanking region of sgk1. (PMID:12376324)
• Powerful stimulating effect of all three isoforms of SGK on K(+) channels. Those effects may participate in regulation of epithelial transport, cell proliferation, and neuromuscular excitability. (PMID:12397388)
• Sgk is a positive regulator of sodium transport. (PMID:12417559)
• Glomerulonephritis leads to glomerular and in some cases to epithelial up-regulation of hSGK1 transcription. (PMID:12435876)
• NHERF2 and SGK1 interact to enhance ROMK1 activity by enhancing abundance of channel protein in cell membrane, allowing integration of genomic regulation and activation of SGK1 and NHERF2 in control of ROMK1 activity and renal K(+) excretion. (PMID:12444200)
• The stimulating effect of SGK1 on the Xenopus oocyte Na(+)/K(+)-ATPase is mimicked by the isoforms SGK2 and SGK3. (PMID:12590200)
• All three members of the SGK family of kinases SGK1-3 and protein kinase B stimulate the slowly activating K(+) channel KCNE1/KCNQ1. The kinases may thus participate in the regulation of KCNE1-dependent transport and excitability. (PMID:12634932)
• SGK-1 phosphorylation of Kir1.1 drives expression on the plasmalemma. The results suggest a possible molecular mechanism for aldosterone-dependent regulation of the secretory potassium channel in the kidney. (PMID:12684516)
• SN1 is a target for the ubiquitin ligase Nedd4-2, which is inactivated by the serum and glucocorticoid inducible kinase SGK1, its isoform SGK3, and protein kinase B. (PMID:12788082)
• up-regulation of SGK1 enhances cell surface epithelial sodium channel expression in collecting duct cells. (PMID:12923071)
• NHERF2, ROMK1, and SGK1 have roles in regulating protein abundance in the plasma membrane and K(+) current (PMID:14623317)
• SGK levels are increased in brains of Huntington’s disease patients; SGK phosphorylates huntingtin at serine 421, protecting striatal neurons against polyQ-huntingtin-induced toxicity. (PMID:14725621)
• SGK1 stimulates the NaPi IIb, at least in part, by phosphorylating and thereby inhibiting Nedd4-2 binding to its target. (PMID:15044175)
• Na+-coupled glucose transporter 1 (SGLT1) was regulated by neuronal cell expressed developmentally downregulated 4-2 (Nedd4-2) and serum- and glucocorticoid-inducible kinase 1 (SGK1) (PMID:15166308)
• cAMP-stimulated Na+ transport in H441 distal lung epithelial cells does not affect levels of this enzyme. (PMID:15208094)
• These findings argue against important role of coding regions of Sgk1 in blood pressure regulation and hypertension and in the hypertension-related progression of renal diseases. (PMID:15304560)
• cAMP regulates ENaC in part by phosphorylation and inhibition of Nedd4-2. Moreover, Nedd4-2 is a central convergence point for kinase regulation of Na(+) transport. (PMID:15328345)
• Sgk1 may modulate insulin action on the cotranslational glycosylation of glycoproteins (PMID:15342340)
• results identify NDRG1 and NDRG2 as physiological substrates for SGK1, and demonstrate that phosphorylation of NDRG1 by SGK1 primes it for phosphorylation by GSK3 (PMID:15461589)
• ClC-Ka/barttin channels are regulated by SGK1 and SGK3, which may thus participate in the regulation of transport in kidney and inner ear. (PMID:15496163)
• Nedd4-2 phosphorylation induces SGK ubiquitination and degradation (PMID:15576372)
• Co-expression of SGK1, but not of SGK2 or SGK3, increased Kv 4.3/KChIP2b channel currents. (PMID:15578212)
• demonstration of the significance of SGK1 and NHERF2 as TRPV5 modulators which are likely to participate in the regulation of calcium homeostasis by 1,25(OH)2D3 (PMID:15665527)
• SGK acts as an oncogene in breast cancer cells through activation of the IKK-NF-kappaB pathway, thereby preventing apoptosis. (PMID:15695387)
• SGK1 activation has a role in oncofetal fibronectin expression (PMID:15721303)
• In conclusion, the kinases SGK1 and SGK3 increase EAAT5 activity by increasing cell surface abundance of the carrier. (PMID:15737648)
• SGK1 and SGK3 increase SLC6A8 activity by increasing the maximal transport rate of the carrier. Deranged SGK1 and/or SGK3 dependent regulation of SLC6A8 may affect energy storage particularly in skeletal muscle, heart, and neurons (PMID:16036218)
• The effects of high glucose on proximal tubular cells proliferation, reduced apoptosis and increased NHE3 mRNA levels are mediated by EGFR-dependent up-regulation of SGK-1 (PMID:16105029)
• key role for sgk1 in the molecular pathway of cell death, in which sgk1 seems to exert a protective role. (PMID:16125969)
• SGK-1 risk carriers are at increased risk of hypertension and are more sensitive to the blood pressure elevating effects associated with hyperinsulinemia (PMID:16221215)
• SGK1 is upregulated in diabetic nephropathy and actively participates in the stimulation of matrix protein deposition in this common deleterious complication of diabetic hyperglycemia. (PMID:16301823)
• SGK1 regulates current amplitudes and kinetic properties of KCNQ4 channel activity, an effect sensitive to mutations in the SGK1 consensus sequence of the channel. (PMID:16301825)
• SGK1 regulates GLUT1 and may contribute to or account for the PI3 kinase-dependent but PKB-independent stimulation of GLUT1 by insulin. (PMID:16443776)
• constitutive ubiquitin-mediated degradation of SGK-1 is an important mechanism regulating its biological activity (PMID:16817852)
• SGK1 is targeted to the endoplasmic reticulum-associated ubiquitin-conjugation machinery by an amphipathic helix (PMID:16847254)
• Acute effect of glucocorticoids on NHE3 is mediated by a glucocorticoid receptor dependent mechanism that activates SGK1 in a nongenomic manner. (PMID:16971495)
• Incubation with glucose, the Ca2+-ionophore ionomycin and the cytokine TGF-beta1 were all found to evoke significant and time-dependent increases in both SGK1 and alphaENaC protein expression. (PMID:17170520)
• Our data do not support that SGK1 gene variations are disease-causing factors in genetically unexplained pseudohypoaldosteronism type 1. (PMID:17317952)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
mus_musculus	Sgk1	ENSMUSG00000019970
rattus_norvegicus	Sgk1	ENSRNOG00000011815
drosophila_melanogaster	CG32944	FBGN0052944
drosophila_melanogaster	dop	FBGN0267390
caenorhabditis_elegans		WBGENE00002192
caenorhabditis_elegans	wts-1	WBGENE00007047
caenorhabditis_elegans		WBGENE00010838
caenorhabditis_elegans		WBGENE00011992

Paralogs (13): MAST4 (ENSG00000069020), MAST2 (ENSG00000086015), MAST3 (ENSG00000099308), SGK2 (ENSG00000101049), SGK3 (ENSG00000104205), DMPK (ENSG00000104936), MAST1 (ENSG00000105613), MASTL (ENSG00000120539), LATS1 (ENSG00000131023), LATS2 (ENSG00000150457), STK32B (ENSG00000152953), STK32C (ENSG00000165752), STK32A (ENSG00000169302)

Protein

Protein identifiers

Serine/threonine-protein kinase Sgk1 — O00141 (reviewed: O00141)

Alternative names: Serum/glucocorticoid-regulated kinase 1

All UniProt accessions (6): E9PJN2, E9PP33, E9PR89, O00141, H0YCJ3, Q7Z3I4

UniProt curated annotations — full annotation on UniProt →

Function. Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na(+) retention, renal K(+) elimination, salt appetite, gastric acid secretion, intestinal Na(+)/H(+) exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarization and memory consolidation. Up-regulates Na(+) channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K(+) channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca(2+) channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na(+)/dicarboxylate cotransporter: SLC13A2/NADC1, Na(+)-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na(+)/K(+) ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport into epithelial cells by enhancing the stability and expression of SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L ubiquitin E3 ligase, promoting its interaction with 14-3-3 proteins, thereby preventing it from binding to SCNN1A/ENAC and targeting it for degradation. Regulates store-operated Ca(+2) entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1 directly via its phosphorylation or indirectly via increased interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and activates MDM2-dependent ubiquitination of p53/TP53. Phosphorylates MAPT/TAU and mediates microtubule depolymerization and neurite formation in hippocampal neurons. Phosphorylates SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates APBB1/FE65 and promotes its localization to the nucleus. Phosphorylates MAPK1/ERK2 and activates it by enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7 and plays an inhibitory role in the NOTCH1 signaling. Phosphorylates FOXO1 resulting in its relocalization from the nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit from the nucleus and interference with FOXO3-dependent transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity. Phosphorylates SLC9A3/NHE3 in response to dexamethasone, resulting in its activation and increased localization at the cell membrane. Phosphorylates CREB1. Necessary for vascular remodeling during angiogenesis. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Isoform 2 exhibited a greater effect on cell plasma membrane expression of SCNN1A/ENAC and Na(+) transport than isoform 1.

Subunit / interactions. Homodimer; disulfide-linked. Forms a trimeric complex with FBXW7 and NOTCH1. Interacts with MAPK3/ERK1, MAPK1/ERK2, MAP2K1/MEK1, MAP2K2/MEK2, NEDD4, NEDD4L, MAPT/TAU, MAPK7, CREB1, SLC9A3R2/NHERF2 and KCNJ1/ROMK1. Associates with the mammalian target of rapamycin complex 2 (mTORC2) via an interaction with MAPKAP1/SIN1.

Subcellular location. Cytoplasm. Nucleus. Endoplasmic reticulum membrane. Cell membrane. Mitochondrion Cell membrane.

Tissue specificity. Expressed in most tissues with highest levels in the pancreas, followed by placenta, kidney and lung. Isoform 2 is strongly expressed in brain and pancreas, weaker in heart, placenta, lung, liver and skeletal muscle.

Post-translational modifications. Regulated by phosphorylation. Activated by phosphorylation on Ser-422 by mTORC2, transforming it into a substrate for PDPK1 which phosphorylates it on Thr-256. Phosphorylation on Ser-397 and Ser-401 are also essential for its activity. Phosphorylation on Ser-78 by MAPK7 is required for growth factor-induced cell cycle progression. Ubiquitinated by NEDD4L; which promotes proteasomal degradation. Ubiquitinated by SYVN1 at the endoplasmic reticulum; which promotes rapid proteasomal degradation and maintains a high turnover rate in resting cells. Isoform 2 shows enhanced stability.

Activity regulation. Two specific sites, one in the kinase domain (Thr-256) and the other in the C-terminal regulatory region (Ser-422), need to be phosphorylated for its full activation. Phosphorylation at Ser-397 and Ser-401 are also essential for its activity. Activated by WNK1, WNK2, WNK3 and WNK4; which promote phosphorylation by mTORC2.

Domain organisation. Isoform 2 subcellular localization at the cell membrane and resistance to proteasomal degradation is mediated by the sequences within the first 120 amino acids.

Induction. Induced by a very large spectrum of stimuli distinct from glucocorticoids and serum. These include aldosterone, cell shrinkage, cell swelling, TGF-beta, ischemic injury of the brain, neuronal excitotoxicity memory consolidation, chronic viral hepatitis, DNA-damaging agents, vitamin D3 psychophysiological stress, iron, glucose, EDN1, CSF2, fibroblast growth factor, platelet-derived growth factor, phorbolesters, follicle-stimulating hormone, sorbitol, heat shock, oxidative stress, UV irradiation, and p53/TP53. Many of these stimuli are highly cell-specific, as is the case, for example for aldosterone, which has been found to stimulate its expression only in cells derived from aldosterone-responsive epithelia. Isoform 2 is not induced by glucocorticoids but by excessive extracellular glucose and by TGFB1, in cultured cells.

Miscellaneous. Produced by alternative promoter usage. Produced by alternative promoter usage. Produced by alternative splicing of isoform 1. Produced by alternative promoter usage.

Similarity. Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family.

Isoforms (5)

UniProt ID	Names	Canonical?
O00141-1	1	yes
O00141-2	2, Sgk1.1, Sgk1_v2
O00141-3	3, Sgk1.2
O00141-4	4
O00141-5	5

RefSeq proteins (5): NP_001137148, NP_001137149, NP_001137150, NP_001278924, NP_005618 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR000961	AGC-kinase_C	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR017892	Pkinase_C	Domain

Pfam: PF00069, PF00433

Enzyme classification (BRENDA):

• EC 2.7.11.1 — non-specific serine/threonine protein kinase (BRENDA: 71 organisms, 682 substrates, 228 inhibitors, 23 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0007–0.64	11
KKRAARATSNVFA	0.013–0.045	3
PAH1 PHOSPHATIDATE PHOSPHATASE	0.0002	2
RRRLSSLRA	0.0036–0.0037	2
GTP	0.46	1
KKRAARASSNVFA	0.02	1
LYS-LYS-PHE-ASN-ARG-THR-LEU-SER-VAL-ALA	0.0093	1
MYELIN BASIC PROTEIN	0.145	1

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (64 total): helix 14, strand 10, modified residue 7, mutagenesis site 7, sequence conflict 6, splice variant 4, domain 2, disulfide bond 2, sequence variant 2, region of interest 2, turn 2, binding site 2, chain 1, short sequence motif 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
2R5T	X-RAY DIFFRACTION	1.9
7PUE	X-RAY DIFFRACTION	2.51
3HDM	X-RAY DIFFRACTION	2.6
3HDN	X-RAY DIFFRACTION	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00141-F1	80.55	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 222 (proton acceptor)

Ligand- & substrate-binding residues (2): 104–112; 127

Post-translational modifications (7): 74, 78, 256, 369, 397, 401, 422

Disulfide bonds (2): 193, 258

Mutagenesis-validated functional residues (7):

Position	Phenotype
127	abolishes enzymatic activity.
256	low activity.
298	abolishes interaction with nedd4 and nedd4l.
422	low activity.
422	10-fold activation.

Function

Pathways and Gene Ontology

Reactome pathways

19 pathways

ID	Pathway
R-HSA-1257604	PIP3 activates AKT signaling
R-HSA-2672351	Stimuli-sensing channels
R-HSA-6804757	Regulation of TP53 Degradation
R-HSA-8986944	Transcriptional Regulation by MECP2
R-HSA-9031628	NGF-stimulated transcription
R-HSA-162582	Signal Transduction
R-HSA-166520	Signaling by NTRKs
R-HSA-187037	Signaling by NTRK1 (TRKA)
R-HSA-198725	Nuclear Events (kinase and transcription factor activation)
R-HSA-212436	Generic Transcription Pathway
R-HSA-3700989	Transcriptional Regulation by TP53
R-HSA-382551	Transport of small molecules
R-HSA-5633007	Regulation of TP53 Activity
R-HSA-6806003	Regulation of TP53 Expression and Degradation
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9006925	Intracellular signaling by second messengers
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases
R-HSA-983712	Ion channel transport

MSigDB gene sets: 680 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, AHRARNT_01, GOBP_MEMORY, TGGTGCT_MIR29A_MIR29B_MIR29C, BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP, GOBP_DIGESTION, BROWNE_HCMV_INFECTION_6HR_DN, GOBP_ACID_SECRETION, IIZUKA_LIVER_CANCER_EARLY_RECURRENCE, GOBP_COGNITION, HNF3ALPHA_Q6, GRUETZMANN_PANCREATIC_CANCER_DN, GOBP_BEHAVIOR, GOBP_REGULATION_OF_BLOOD_PRESSURE, GOBP_CIRCULATORY_SYSTEM_PROCESS

GO Biological Process (19): regulation of cell growth (GO:0001558), protein phosphorylation (GO:0006468), sodium ion transport (GO:0006814), apoptotic process (GO:0006915), DNA damage response (GO:0006974), long-term memory (GO:0007616), regulation of blood pressure (GO:0008217), positive regulation of transporter activity (GO:0032411), intracellular signal transduction (GO:0035556), regulation of cell population proliferation (GO:0042127), regulation of apoptotic process (GO:0042981), neuron projection morphogenesis (GO:0048812), regulation of catalytic activity (GO:0050790), obsolete regulation of DNA-binding transcription factor activity (GO:0051090), regulation of gastric acid secretion (GO:0060453), renal sodium ion absorption (GO:0070294), regulation of signal transduction by p53 class mediator (GO:1901796), cellular response to aldosterone (GO:1904045), regulation of cell migration (GO:0030334)

GO Molecular Function (14): protein serine/threonine kinase activity (GO:0004674), protein serine/threonine/tyrosine kinase activity (GO:0004712), calcium channel regulator activity (GO:0005246), ATP binding (GO:0005524), potassium channel regulator activity (GO:0015459), sodium channel regulator activity (GO:0017080), chloride channel regulator activity (GO:0017081), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), phosphatidylinositol binding (GO:0035091)

GO Cellular Component (10): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), mitochondrion (GO:0005739), endoplasmic reticulum membrane (GO:0005789), cytosol (GO:0005829), plasma membrane (GO:0005886), nuclear speck (GO:0016607), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-14 pathways:

Category	Pathways
Generic Transcription Pathway	2
Signal Transduction	2
Intracellular signaling by second messengers	1
Ion channel transport	1
Regulation of TP53 Expression and Degradation	1
Nuclear Events (kinase and transcription factor activation)	1
Signaling by Receptor Tyrosine Kinases	1
Signaling by NTRKs	1
Signaling by NTRK1 (TRKA)	1
RNA Polymerase II Transcription	1
Transcriptional Regulation by TP53	1
Regulation of TP53 Activity	1
Gene expression (Transcription)	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ion channel regulator activity	4
cellular anatomical structure	4
protein kinase activity	3
intracellular membrane-bounded organelle	3
cytoplasm	3
intracellular anatomical structure	2
catalytic activity	2
cell growth	1
regulation of growth	1
regulation of cellular component organization	1
phosphorylation	1
protein modification process	1
metal ion transport	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cellular response to stress	1
memory	1
blood circulation	1
regulation of biological quality	1
transporter activity	1
positive regulation of molecular function	1
positive regulation of transport	1
signal transduction	1
cell population proliferation	1
regulation of cellular process	1
apoptotic process	1
regulation of programmed cell death	1
neuron projection development	1
plasma membrane bounded cell projection morphogenesis	1
regulation of molecular function	1
gastric acid secretion	1
regulation of digestive system process	1
regulation of secretion	1
renal sodium ion transport	1
renal absorption	1
signal transduction by p53 class mediator	1
regulation of intracellular signal transduction	1
cellular response to mineralocorticoid stimulus	1
cellular response to alcohol	1

Protein interactions and networks

STRING

3220 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SGK1	NEDD4L	Q96PU5	952
SGK1	TSC22D3	Q99576	866
SGK1	MAPKAP1	Q9BPZ7	851
SGK1	DEPTOR	Q8TB45	835
SGK1	FKBP5	Q13451	826
SGK1	SCNN1B	P51168	802
SGK1	RICTOR	Q6R327	800
SGK1	FOXO3	O43524	781
SGK1	SCNN1G	P51170	780
SGK1	KCNJ1	P48048	770
SGK1	PRR5	P85299	769
SGK1	MLST8	Q9BVC4	746
SGK1	RPTOR	Q8N122	739
SGK1	MTOR	P42345	731
SGK1	SCNN1A	P37088	717

IntAct

83 interactions, top by confidence:

A	B	Type	Score
TSC2	SGK1	psi-mi:“MI:0915”(physical association)	0.560
TSC2	SGK1	psi-mi:“MI:2364”(proximity)	0.560
SGK1	MAL2	psi-mi:“MI:0915”(physical association)	0.560
SGK1	CETN3	psi-mi:“MI:0915”(physical association)	0.560
SGK1	NDRG4	psi-mi:“MI:0915”(physical association)	0.560
SGK1	FKBP5	psi-mi:“MI:0915”(physical association)	0.560
SGK1	Wnk4	psi-mi:“MI:0217”(phosphorylation reaction)	0.540
Wnk4	SGK1	psi-mi:“MI:0915”(physical association)	0.540
SGK1	RABAC1	psi-mi:“MI:0915”(physical association)	0.490
RABAC1	SGK1	psi-mi:“MI:0915”(physical association)	0.490
CREB1	SGK1	psi-mi:“MI:0915”(physical association)	0.490
SGK1	CREB1	psi-mi:“MI:0217”(phosphorylation reaction)	0.490
PDPK1	SGK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
SGK1	GADD45G	psi-mi:“MI:0915”(physical association)	0.440
GADD45G	SGK1	psi-mi:“MI:0403”(colocalization)	0.440
SGK1	MAPT	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
MTOR	SGK1	psi-mi:“MI:0915”(physical association)	0.400
SGK1	ECH1	psi-mi:“MI:0915”(physical association)	0.400
HSP90AB1	SGK1	psi-mi:“MI:0915”(physical association)	0.400
	SGK1	psi-mi:“MI:0915”(physical association)	0.400
SGK1		psi-mi:“MI:0915”(physical association)	0.400
SGK1	MAGEA1	psi-mi:“MI:0915”(physical association)	0.370
SGK1	Rabac1	psi-mi:“MI:0915”(physical association)	0.370
SGK1	Tmem109	psi-mi:“MI:0915”(physical association)	0.370
SGK1	TMEM184C	psi-mi:“MI:0915”(physical association)	0.370
	SGK1	psi-mi:“MI:0914”(association)	0.350
SGK1	HRAS	psi-mi:“MI:0914”(association)	0.350

BioGRID (119): MAPT (Biochemical Activity), YWHAZ (Affinity Capture-Western), YWHAQ (Affinity Capture-Western), SGK1 (Affinity Capture-Western), SGK1 (Biochemical Activity), RPTOR (Affinity Capture-Western), MTOR (Affinity Capture-Western), AKT1S1 (Affinity Capture-Western), SGK1 (Affinity Capture-Western), CDKN1B (Biochemical Activity), SGK1 (Biochemical Activity), NDRG1 (Biochemical Activity), SGK1 (Biochemical Activity), NEDD4L (Biochemical Activity), ARL5B (Affinity Capture-MS)

ESM2 similar proteins: A0A509AKL0, A5K0N4, A8X6H1, A8X6H4, A8XNJ6, O00141, O61267, O64629, P05130, P05987, P09215, P20444, P21901, P23298, P24604, P24723, P28867, P42680, P54644, P62345, P81900, P90980, Q05655, Q0CIC7, Q13237, Q16974, Q25378, Q26619, Q2PJ68, Q4R633, Q54CY9, Q55GV3, Q5BKK4, Q5F3L1, Q5PU49, Q5Q0U5, Q61410, Q64595, Q64617, Q6GLY8

Diamond homologs: A1A4I4, A1Z7T0, A1Z9X0, A7MB74, A7MBL8, A8KBH6, A8WUG4, F1M7Y5, O00141, O08874, O19111, O42632, P04409, P05126, P05128, P05129, P05130, P05696, P05771, P05772, P09215, P09216, P09217, P10102, P10829, P10830, P13677, P13678, P16054, P17252, P20444, P23298, P24583, P24723, P28867, P31748, P31749, P31750, P31751, P34722

SIGNOR signaling

71 interactions.

A	Effect	B	Mechanism
SGK1	“down-regulates activity”	MAP3K3	phosphorylation
MAPK7	up-regulates	SGK1	phosphorylation
SGK1	up-regulates	NEDD4L	phosphorylation
SGK1	down-regulates	HTT	phosphorylation
SGK1	up-regulates	NDRG2	phosphorylation
SGK1	down-regulates	NEDD4L	phosphorylation
SGK1	down-regulates	MAPT	phosphorylation
SGK1	down-regulates	NDRG1	phosphorylation
SGK1	up-regulates	FBXW7	phosphorylation
MTOR	up-regulates	SGK1	phosphorylation
SGK1	down-regulates	CDKN1B	phosphorylation
SGK1	“down-regulates activity”	CDKN1B	phosphorylation
SGK1	up-regulates	NDRG1	phosphorylation
mTORC2	up-regulates	SGK1	phosphorylation
SGK1	“down-regulates activity”	FOXO3	phosphorylation
PDPK1	up-regulates	SGK1	phosphorylation
SGK1	“up-regulates activity”	NR3C1	phosphorylation
SGK1	down-regulates	GLI1	binding
SGK1	down-regulates	SMO	binding
SGK1	“down-regulates activity”	NEDD4L	phosphorylation

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 4 cancer types — DLBCLNOS, MLYM, NHL, PRCC.

Clinical variants and AI predictions

ClinVar

81 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	28
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
800349	NM_001143676.3(SGK1):c.1379A>G (p.Asn460Ser)	Likely pathogenic

SpliceAI

900 predictions. Top by Δscore:

Variant	Effect	Δscore
6:134170431:CCACT:C	acceptor_gain	1.0000
6:134170432:CACT:C	acceptor_gain	1.0000
6:134170432:CACTC:C	acceptor_gain	1.0000
6:134170434:CT:C	acceptor_gain	1.0000
6:134170435:TCTG:T	acceptor_loss	1.0000
6:134170436:C:CC	acceptor_gain	1.0000
6:134170436:C:T	acceptor_loss	1.0000
6:134170437:T:A	acceptor_loss	1.0000
6:134170438:G:C	acceptor_gain	1.0000
6:134170442:C:CT	acceptor_gain	1.0000
6:134170443:G:T	acceptor_gain	1.0000
6:134170818:ATACT:A	donor_loss	1.0000
6:134170820:ACTC:A	donor_loss	1.0000
6:134170821:CTC:C	donor_loss	1.0000
6:134170822:TCA:T	donor_loss	1.0000
6:134170823:CA:C	donor_loss	1.0000
6:134170824:A:AC	donor_gain	1.0000
6:134170824:A:AT	donor_loss	1.0000
6:134170825:C:A	donor_loss	1.0000
6:134170825:C:CC	donor_gain	1.0000
6:134170825:CCA:C	donor_gain	1.0000
6:134170825:CCACA:C	donor_gain	1.0000
6:134170912:CCAT:C	acceptor_gain	1.0000
6:134170913:CAT:C	acceptor_gain	1.0000
6:134170913:CATC:C	acceptor_gain	1.0000
6:134170914:ATCTG:A	acceptor_loss	1.0000
6:134170915:TC:T	acceptor_loss	1.0000
6:134170916:C:CC	acceptor_gain	1.0000
6:134170916:CTGTT:C	acceptor_loss	1.0000
6:134170917:T:C	acceptor_loss	1.0000

AlphaMissense

3509 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:134170301:A:C	F421L	1.000
6:134170301:A:T	F421L	1.000
6:134170302:A:G	F421S	1.000
6:134170303:A:G	F421L	1.000
6:134170310:G:C	F418L	1.000
6:134170310:G:T	F418L	1.000
6:134170311:A:G	F418S	1.000
6:134170312:A:G	F418L	1.000
6:134170397:A:C	F389L	1.000
6:134170397:A:T	F389L	1.000
6:134170398:A:G	F389S	1.000
6:134170399:A:G	F389L	1.000
6:134171066:A:G	L332P	1.000
6:134171069:A:G	L331P	1.000
6:134171146:C:A	M305I	1.000
6:134171146:C:G	M305I	1.000
6:134171146:C:T	M305I	1.000
6:134171170:A:C	F297L	1.000
6:134171170:A:T	F297L	1.000
6:134171172:A:G	F297L	1.000
6:134171172:A:T	F297I	1.000
6:134171174:G:T	P296H	1.000
6:134171650:A:C	M290R	1.000
6:134171668:C:T	G284E	1.000
6:134171669:C:G	G284R	1.000
6:134171669:C:T	G284R	1.000
6:134171673:G:C	C282W	1.000
6:134171675:A:G	C282R	1.000
6:134171676:C:A	W281C	1.000
6:134171676:C:G	W281C	1.000

dbSNP variants (sampled 300 via entrez): RS1000071493 (6:134263738 G>T), RS1000088374 (6:134301635 G>C,T), RS1000093736 (6:134307275 G>A), RS1000106332 (6:134219118 G>C), RS1000114897 (6:134215363 A>C,T), RS1000119177 (6:134214216 G>A,T), RS1000119535 (6:134227876 T>C), RS1000132917 (6:134174325 G>A,C), RS1000147595 (6:134307586 T>G), RS1000180293 (6:134314021 A>G), RS1000209038 (6:134264155 G>C), RS1000219694 (6:134194758 A>G), RS1000234069 (6:134314303 C>T), RS1000250736 (6:134194474 T>C), RS1000266092 (6:134221761 T>A)

Disease associations

OMIM: gene MIM:602958 | disease phenotypes: MIM:254500

GenCC curated gene-disease

Mondo (1): plasma cell myeloma (MONDO:0009693)

Orphanet (2): Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST001538_30	Immune reponse to smallpox (secreted IFN-alpha)	4.000000e-07
GCST002812_4	Schizophrenia (inflammation and infection response interaction)	8.000000e-06
GCST003225_19	Pelvic organ prolapse (moderate/severe)	6.000000e-06
GCST003225_5	Pelvic organ prolapse (moderate/severe)	4.000000e-06
GCST003226_1	Pelvic organ prolapse	7.000000e-06
GCST003226_7	Pelvic organ prolapse	2.000000e-06
GCST004581_3	Body mass index (smoking years interaction)	2.000000e-06
GCST006434_4	Systolic blood pressure x alcohol consumption interaction (2df test)	2.000000e-09
GCST006988_119	Blond vs. brown/black hair color	2.000000e-08
GCST010002_335	Refractive error	6.000000e-10
GCST010796_2268	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-08
GCST010796_2269	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2270	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2271	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-09
GCST010796_2272	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_2273	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-09
GCST90000015_18	Parkinson’s disease motor subtype (tremor to postural instability/gait difficulty score ratio)	7.000000e-06

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004645	response to vaccine
EFO:0004873	cytokine measurement
EFO:0007047	Toxoplasma gondii seropositivity
EFO:0004340	body mass index
EFO:0004329	alcohol drinking
EFO:0006335	systolic blood pressure
EFO:0003924	hair color
EFO:0004327	electrocardiography
EFO:0600011	Parkinson’s disease symptom measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2343 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,624 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL3137336	UPROSERTIB	2	1,624

Clinical evidence (CIViC)

Drug × variant × indication: 2 predictive associations from 3 curated evidence items.

Variant	Therapy	Indication	Effect	Level	CIViC
SGK1 Overexpression	Alpelisib	Breast Cancer	Resistance	CIViC B	EID1730 +1
SGK1 Overexpression	SGK1-Inh + Alpelisib	Breast Cancer	Sensitivity/Response	CIViC D	EID1731

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — SGK family

Most potent curated ligand interactions (5 total), top 5:

Ligand	Action	Affinity	Parameter
compound 14n [PMID: 25589934]	Inhibition	9.0	pIC50
Sanofi-14h	Inhibition	8.0	pIC50
PO-322	Inhibition	7.27	pIC50
GSK650394	Inhibition	7.21	pIC50
EMD638683	Inhibition	5.52	pIC50

Binding affinities (BindingDB)

571 measured of 661 human assays (661 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-[4-(3-amino-4-ethoxy-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-5-chloro-2,4-difluorobenzenesulfonamide	IC50	0.57 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
5-chloro-2-fluoro-N-[4-[4-(1-methylpiperidin-4-yl)oxy-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	IC50	0.59 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
5-chloro-N-[4-[4-(3,3-difluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-2-fluorobenzenesulfonamide	IC50	0.76 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-[4-[[3-(aminomethyl)oxetan-3-yl]methoxy]-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]-2-chloro-5-methoxybenzenesulfonamide	IC50	0.85 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-amino-2H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-5-chloro-2-fluorobenzenesulfonamide	IC50	1 nM	US-9221828: N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides as pharmaceuticals
5-chloro-2-cyano-N-[4-[4-[(3-hydroxycyclohexyl)amino]-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	IC50	1.1 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-[4-(3,3-difluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-2-fluoro-5-methylbenzenesulfonamide	IC50	1.1 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-cyano-N-[4-[4-(3-fluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methylbenzenesulfonamide	IC50	1.1 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[6-[4-[(2,5-dichlorophenyl)sulfonylamino]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]cyclopropanecarboxamide	IC50	1.1 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-chloro-N-[4-(4-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-5-methylbenzenesulfonamide	IC50	1.2 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-fluoro-5-methyl-N-[4-(4-piperidin-3-yloxy-1H-pyrazolo[5,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	IC50	1.2 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-[4-(3,3-difluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-2-fluoro-5-methoxybenzenesulfonamide	IC50	1.3 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-cyano-N-[4-[4-(3,3-difluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methylbenzenesulfonamide	IC50	1.3 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
5-chloro-2-fluoro-N-[4-(3-methyl-4-piperidin-3-yloxy-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	IC50	1.3 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-cyano-N-[4-[4-(1-cyclopropylpiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[4,3-c]pyridin-6-yl]phenyl]-5-methylbenzenesulfonamide	IC50	1.3 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
5-chloro-2-fluoro-N-[4-[4-(3-hydroxypropylamino)-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	IC50	1.4 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-cyano-N-[4-[4-[(3-hydroxycyclohexyl)amino]-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methylbenzenesulfonamide	IC50	1.4 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-Chloro-N-[2-fluoro-4-(3-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-phenyl]-5-methoxy-benzenesulfonamide	IC50	1.4 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2,5-dichloro-N-[4-[4-(pyridin-4-ylmethylamino)-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(4-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-2-fluoro-5-methoxybenzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-[4-(3,3-difluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-2-fluorobenzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-chloro-N-[4-[4-(3,3-difluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methoxybenzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2,5-difluoro-N-[4-[4-(3-fluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-amino-4-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-2-fluoro-5-methylbenzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-Amino-4-trifluoromethyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-phenyl]-5-chloro-2-fluoro-benzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-amino-4-propoxy-1H-pyrazolo[4,3-c]pyridin-6-yl)phenyl]-5-chloro-2,4-difluorobenzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-fluoro-N-[4-(4-methoxy-1H-pyrazolo[5,4-d]pyrimidin-6-yl)phenyl]-5-methylbenzenesulfonamide	IC50	1.5 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-[4-(azetidin-3-ylmethoxy)-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]-2,5-difluorobenzenesulfonamide	IC50	1.6 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-fluoro-5-methyl-N-[4-(3-methyl-4-piperidin-3-yloxy-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	IC50	1.6 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-Amino-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-phenyl]-5-chloro-2,4-difluoro-benzenesulfonamide	IC50	1.6 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-Amino-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-phenyl]-5-chloro-2-cyano-benzenesulfonamide	IC50	1.6 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-amino-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-2-cyano-5-methylbenzenesulfonamide	IC50	1.6 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[6-[4-[(2,5-Dichlorophenyl)sulfonylamino]phenyl]-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]tetrahydropyran-4-carboxamide	IC50	1.6 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-cyano-N-[4-[4-[(4-hydroxycyclohexyl)amino]-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methylbenzenesulfonamide	IC50	1.7 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-chloro-N-[4-[4-(4-hydroxycyclohexyl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methoxybenzenesulfonamide	IC50	1.7 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-[4-(3,3-difluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-2,5-difluorobenzenesulfonamide	IC50	1.7 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-amino-1H-pyrazolo[4,3-c]pyridin-6-yl)phenyl]-2,5-dichlorobenzenesulfonamide	IC50	1.7 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-[3-amino-4-(trifluoromethyl)-1H-pyrazolo[4,3-c]pyridin-6-yl]phenyl]-2-cyano-5-methylbenzenesulfonamide	IC50	1.7 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
N-[4-(3-amino-4-ethoxy-1H-pyrazolo[4,3-c]pyridin-6-yl)phenyl]-2-fluoro-5-methoxybenzenesulfonamide	IC50	1.7 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-fluoro-N-[4-[4-(3-fluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	IC50	1.8 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-fluoro-N-[4-[4-[3-hydroxy-2-(hydroxymethyl)propoxy]-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methylbenzenesulfonamide	IC50	1.8 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2,5-dichloro-N-[2-fluoro-4-(3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	IC50	1.8 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
5-Chloro-2,4-difluoro-N-[4-(3-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-phenyl]-benzenesulfonamide	IC50	1.8 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-chloro-5-methoxy-N-[4-(4-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	IC50	1.8 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2,5-dichloro-N-[4-[3-methyl-4-(2,2,6,6-tetramethylpiperidin-4-yl)oxy-2H-pyrazolo[4,3-c]pyridin-6-yl]phenyl]benzenesulfonamide	IC50	1.8 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-fluoro-5-methoxy-N-[4-[3-methyl-4-(1,2,2,6,6-pentamethylpiperidin-4-yl)oxy-2H-pyrazolo[4,3-c]pyridin-6-yl]phenyl]benzenesulfonamide	IC50	1.8 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2,3-dichloro-N-[4-(3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	IC50	1.9 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-fluoro-N-[4-[4-(3-fluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methoxybenzenesulfonamide	IC50	1.9 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
2-fluoro-5-methyl-N-[4-[3-methyl-4-[(2-oxo-1H-pyridin-4-yl)oxy]-2H-pyrazolo[4,3-c]pyridin-6-yl]phenyl]benzenesulfonamide	IC50	1.9 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
5-chloro-2-cyano-N-[4-[4-(4-hydroxycyclohexyl)oxy-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	IC50	2 nM	US-9718825: N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals

ChEMBL bioactivities

904 potent at pChembl≥5 of 915 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.24	IC50	0.57	nM	CHEMBL5863871
9.23	IC50	0.59	nM	CHEMBL5802087
9.12	IC50	0.76	nM	CHEMBL5085476
9.07	IC50	0.85	nM	CHEMBL5776800
9.00	IC50	1	nM	CHEMBL3092468
9.00	IC50	1	nM	CHEMBL3356029
9.00	IC50	1	nM	CHEMBL5093306
9.00	IC50	1	nM	CHEMBL5087657
9.00	IC50	1	nM	CHEMBL5075992
9.00	IC50	1	nM	CHEMBL5075362
9.00	IC50	1	nM	CHEMBL5074684
9.00	IC50	1	nM	CHEMBL5088069
9.00	IC50	1	nM	CHEMBL5087162
9.00	IC50	1	nM	CHEMBL5081869
9.00	IC50	1	nM	CHEMBL5083625
9.00	IC50	1	nM	CHEMBL5085476
9.00	IC50	1	nM	CHEMBL5070612
8.96	IC50	1.1	nM	CHEMBL5775294
8.96	IC50	1.1	nM	CHEMBL5966376
8.96	IC50	1.1	nM	CHEMBL5780093
8.96	IC50	1.1	nM	CHEMBL5913005
8.92	IC50	1.2	nM	CHEMBL5898456
8.92	IC50	1.2	nM	CHEMBL5943271
8.89	IC50	1.3	nM	CHEMBL5988036
8.89	IC50	1.3	nM	CHEMBL5768922
8.89	IC50	1.3	nM	CHEMBL5081869
8.89	IC50	1.3	nM	CHEMBL6065816
8.85	IC50	1.4	nM	CHEMBL5911107
8.85	IC50	1.4	nM	CHEMBL5765800
8.85	IC50	1.4	nM	CHEMBL5746702
8.83	IC50	1.47	nM	STAUROSPORINE
8.82	IC50	1.5	nM	CHEMBL3355031
8.82	IC50	1.5	nM	CHEMBL5785037
8.82	IC50	1.5	nM	CHEMBL5958106
8.82	IC50	1.5	nM	CHEMBL5982568
8.82	IC50	1.5	nM	CHEMBL5837773
8.82	IC50	1.5	nM	CHEMBL6003000
8.82	IC50	1.5	nM	CHEMBL5789079
8.82	IC50	1.5	nM	CHEMBL6056857
8.82	IC50	1.5	nM	CHEMBL5838749
8.80	IC50	1.6	nM	CHEMBL5846227
8.80	IC50	1.6	nM	CHEMBL5994877
8.80	IC50	1.6	nM	CHEMBL5086929
8.80	IC50	1.6	nM	CHEMBL5082336
8.80	IC50	1.6	nM	CHEMBL5844362
8.80	IC50	1.6	nM	CHEMBL6031107
8.77	IC50	1.7	nM	CHEMBL5865409
8.77	IC50	1.7	nM	CHEMBL5893172
8.77	IC50	1.7	nM	CHEMBL5905959
8.77	IC50	1.7	nM	CHEMBL5894177

PubChem BioAssay actives

324 with measured affinity, of 1494 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-2,5-dichlorothiophene-3-sulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-2-chlorobenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-2,5-dichlorobenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-2-fluoro-5-(trifluoromethyl)benzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-2-fluorobenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-2,5-difluorobenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-2-chloro-5-methoxybenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-5-bromo-2-chlorobenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-5-chloro-2-fluorobenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0010	uM
5-chloro-N-[4-[4-(3,3-difluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-2-fluorobenzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
5-chloro-2-fluoro-N-[4-(3-methyl-4-piperidin-3-yloxy-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
5-chloro-2-fluoro-N-[4-[4-[3-hydroxy-2-(hydroxymethyl)propoxy]-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-[(3R)-pyrrolidin-3-yl]-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
5-chloro-2-fluoro-N-[4-(3-methyl-4-piperidin-4-yloxy-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
5-chloro-2-fluoro-N-[4-[4-(3-fluoropiperidin-4-yl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
N-(2-aminoethyl)-6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-(1H-1,2,4-triazol-5-ylmethyl)-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-(2-hydroxyethyl)-N-methyl-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-(1,3-oxazol-4-ylmethyl)-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-(1H-imidazol-2-ylmethyl)-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-(1-methylazetidin-3-yl)-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
5-chloro-2-fluoro-N-[4-[3-methyl-4-[(1-propan-2-ylazetidin-3-yl)methoxy]-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
N-[1-(cyclopropylmethyl)pyrrolidin-3-yl]-6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-[(1-ethylpyrrolidin-3-yl)methyl]-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-[1-(2-hydroxyethyl)pyrrolidin-3-yl]-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
6-[4-[(2,3-dichlorophenyl)sulfonylamino]phenyl]-N-(1-methylpyrrolidin-3-yl)-1H-pyrazolo[5,4-b]pyridine-4-carboxamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
N-[4-[4-[[3-(aminomethyl)oxetan-3-yl]methoxy]-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-chloro-2-fluorobenzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
N-[4-(3-amino-2H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-5-chloro-2-fluorobenzenesulfonamide	1056407: Inhibition of recombinant human SGK-1 expressed in baculovirus expression system using (5(6)-carboxyfluorescein)-RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay	ic50	0.0010	uM
5-chloro-2-fluoro-N-[4-[4-(4-hydroxycyclohexyl)oxy-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0010	uM
N-[4-[4-(3-aminopropoxy)-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]-2,5-dichlorobenzenesulfonamide	1177119: Inhibition of SGK1 (unknown origin) assessed as substrate phosphorylation	ic50	0.0012	uM
2,5-dichloro-N-[4-(3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]benzenesulfonamide	1177119: Inhibition of SGK1 (unknown origin) assessed as substrate phosphorylation	ic50	0.0012	uM
5-chloro-2-cyano-N-[4-[4-(4-hydroxycyclohexyl)oxy-1H-pyrazolo[5,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	1177119: Inhibition of SGK1 (unknown origin) assessed as substrate phosphorylation	ic50	0.0015	uM
2-fluoro-N-[4-[4-(4-hydroxycyclohexyl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-5-methoxybenzenesulfonamide	1177119: Inhibition of SGK1 (unknown origin) assessed as substrate phosphorylation	ic50	0.0015	uM
2-fluoro-N-[4-(4-methoxy-1H-pyrazolo[5,4-d]pyrimidin-6-yl)phenyl]-5-methylbenzenesulfonamide	1177119: Inhibition of SGK1 (unknown origin) assessed as substrate phosphorylation	ic50	0.0015	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	2151341: Inhibition of SGK1 (unknown origin) in the presence of [33P]ATP by kinase hotspot assay	ic50	0.0015	uM
N-[4-(3-amino-4-cyclopropyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl]-2-cyano-5-methoxybenzenesulfonamide	1177119: Inhibition of SGK1 (unknown origin) assessed as substrate phosphorylation	ic50	0.0015	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-2,3-dichlorobenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0020	uM
N-[4-(3-amino-1H-indazol-6-yl)phenyl]-5-chloro-2-cyanobenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0020	uM
5-chloro-2-fluoro-N-[4-[4-(4-hydroxycyclohexyl)oxy-3-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0020	uM
5-chloro-2-fluoro-N-[4-[3-methyl-4-(morpholin-2-ylmethoxy)-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0020	uM
5-chloro-2-fluoro-N-[4-[3-methyl-4-(1,2,2,6,6-pentamethylpiperidin-4-yl)oxy-2H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0020	uM
2,3-dichloro-N-[4-[4-(piperazine-1-carbonyl)-1H-pyrazolo[5,4-b]pyridin-6-yl]phenyl]benzenesulfonamide	1821042: Inhibition of recombinant human SGK1 expressed in baculovirus expression system using 5-carboxyfluorescein -RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition in presence of 10 uM ATP and measured after 60 mins by microfluidics assay	ic50	0.0020	uM
N-[4-(3-amino-2H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-2-cyano-5-methoxybenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0020	uM
N-[4-(3-amino-2H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]-2-fluoro-5-methoxybenzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0020	uM
N-[4-(3-amino-2H-pyrazolo[3,4-b]pyrazin-6-yl)-2-fluorophenyl]-5-chloro-2-fluorobenzenesulfonamide	1056407: Inhibition of recombinant human SGK-1 expressed in baculovirus expression system using (5(6)-carboxyfluorescein)-RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay	ic50	0.0020	uM
N-[4-(3-amino-2H-pyrazolo[3,4-b]pyrazin-6-yl)-2-fluorophenyl]-2,5-dichlorobenzenesulfonamide	1056407: Inhibition of recombinant human SGK-1 expressed in baculovirus expression system using (5(6)-carboxyfluorescein)-RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay	ic50	0.0020	uM
2,5-dichloro-N-[4-(3-methyl-2H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]benzenesulfonamide	1177297: Inhibition of human SGK1 using fluo-5(6)-carboxyfluorescein)-RPRAATF-NH2 fluorescently labeled peptide by substrate phosphorylation assay in presence of 10 uM ATP	ic50	0.0020	uM
2-fluoro-5-methyl-N-[4-(3-methyl-2H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]benzenesulfonamide	1056407: Inhibition of recombinant human SGK-1 expressed in baculovirus expression system using (5(6)-carboxyfluorescein)-RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay	ic50	0.0020	uM
2-chloro-5-methoxy-N-[4-(3-methyl-2H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]benzenesulfonamide	1056407: Inhibition of recombinant human SGK-1 expressed in baculovirus expression system using (5(6)-carboxyfluorescein)-RPRAATF-NH2 as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by fluorescence assay	ic50	0.0020	uM

CTD chemical–gene interactions

164 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, decreases reaction, affects reaction, increases expression, affects cotreatment	11
Benzo(a)pyrene	decreases expression, increases expression, affects methylation	8
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	8
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, increases expression	6
bisphenol A	decreases methylation, increases expression, decreases reaction, affects expression, affects cotreatment (+2 more)	5
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	5
Fulvestrant	decreases expression, decreases reaction, increases expression, affects cotreatment, affects methylation	5
Cyclosporine	decreases expression	4
trichostatin A	increases expression, affects cotreatment	3
Irinotecan	increases expression	3
Formaldehyde	increases expression	3
Cadmium Chloride	decreases expression, increases expression, increases phosphorylation, decreases reaction, affects cotreatment	3
Raloxifene Hydrochloride	affects cotreatment, increases expression, decreases expression, affects expression	3
Particulate Matter	increases abundance, affects cotreatment, decreases expression	3
lead acetate	decreases expression, affects cotreatment	2
ochratoxin A	decreases expression	2
potassium chromate(VI)	affects cotreatment, increases expression, decreases expression	2
nickel sulfate	increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
chromium hexavalent ion	affects expression, increases abundance, increases expression	2
Arsenic Trioxide	increases expression	2
Arsenic	increases abundance, affects expression, affects cotreatment, decreases expression	2
Atrazine	increases expression, affects reaction	2
Copper	affects binding, increases expression	2
Dexamethasone	increases expression, decreases reaction	2
Ethyl Methanesulfonate	decreases expression, increases expression	2
Mestranol	affects reaction, increases expression	2
Ouabain	decreases reaction, increases transport, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Progesterone	affects reaction, increases expression, decreases reaction	2

ChEMBL screening assays

538 unique, capped per target: 535 binding, 2 admet, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1003328	Binding	Inhibition of SGK1 at 1 uM relative to control	Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. — J Med Chem
CHEMBL4407586	ADMET	Inhibition of recombinant human GST-tagged SGK catalytic domain (60 to 431 residues) expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 06 peptide as substrate measured after 1 hr by Z’-lyte assay relative to con	Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase. — J Med Chem
CHEMBL5464247	Functional	SGK1 degradation assay	Data for DCP probe SGK3-PROTAC1

Cellosaurus cell lines

7 cell lines: 6 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D8A5	Ubigene A-549 SGK1 KO	Cancer cell line	Male
CVCL_D8V2	Ubigene HCT 116 SGK1 KO	Cancer cell line	Male
CVCL_D9RI	Ubigene HEK293 SGK1 KO	Transformed cell line	Female
CVCL_E1CE	Ubigene SU-DHL-4 SGK1 KO	Cancer cell line	Male
CVCL_TK84	HAP1 SGK1 (-) 1	Cancer cell line	Male
CVCL_TK85	HAP1 SGK1 (-) 2	Cancer cell line	Male
CVCL_TK86	HAP1 SGK1 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00104104	PHASE4	COMPLETED	A Multiple Myeloma Trial in Patients With Bone Metastases
NCT00211211	PHASE4	COMPLETED	FREE Study - Fracture Reduction Evaluation
NCT00242528	PHASE4	WITHDRAWN	Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
NCT00257114	PHASE4	COMPLETED	Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00352703	PHASE4	COMPLETED	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00361140	PHASE4	COMPLETED	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00622505	PHASE4	COMPLETED	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
NCT00652041	PHASE4	COMPLETED	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00733538	PHASE4	COMPLETED	Stage I Multiple Myeloma Treatment
NCT01087008	PHASE4	COMPLETED	Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01249690	PHASE4	UNKNOWN	Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
NCT01410929	PHASE4	WITHDRAWN	Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma
NCT01731886	PHASE4	COMPLETED	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01868828	PHASE4	UNKNOWN	A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
NCT02268890	PHASE4	COMPLETED	A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02286830	PHASE4	COMPLETED	Prolonged Protection From Bone Disease in Multiple Myeloma
NCT02559154	PHASE4	UNKNOWN	Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02577783	PHASE4	UNKNOWN	PDD vs PAD to Treat Initially Diagnosed MM
NCT02773550	PHASE4	TERMINATED	Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02958969	PHASE4	COMPLETED	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
NCT03173092	PHASE4	TERMINATED	A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
NCT03619252	PHASE4	COMPLETED	Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT03768960	PHASE4	COMPLETED	A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03829371	PHASE4	ACTIVE_NOT_RECRUITING	STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT03908138	PHASE4	UNKNOWN	RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT04217967	PHASE4	COMPLETED	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
NCT04952766	PHASE4	COMPLETED	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT04989140	PHASE4	UNKNOWN	Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT05183139	PHASE4	WITHDRAWN	A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
NCT05201781	PHASE4	RECRUITING	A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05429515	PHASE4	NOT_YET_RECRUITING	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
NCT05511428	PHASE4	COMPLETED	Home Based Daratumumab Administration for Patients With Multiple Myeloma
NCT05545202	PHASE4	UNKNOWN	A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
NCT05555329	PHASE4	COMPLETED	Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
NCT05722405	PHASE4	RECRUITING	Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05855122	PHASE4	UNKNOWN	Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05944783	PHASE4	NOT_YET_RECRUITING	Bioequivalence Studies of Dasatinib 100 Mg
NCT06057402	PHASE4	RECRUITING	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06251076	PHASE4	RECRUITING	Plan Development for Giving Teclistamab in the Outpatient Setting